Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

83.3%

5 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05177107Phase 2Terminated

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Role: lead

NCT05269121Phase 1Withdrawn

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Role: lead

NCT05269134Phase 2Withdrawn

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

Role: lead

NCT04287478Phase 1Terminated

Bacteriophage Therapy in Patients With Urinary Tract Infections

Role: lead

NCT04787250Phase 1Withdrawn

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

Role: lead

NCT04636554Unknown

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Role: lead

All 6 trials loaded